Ludwig, J. A., Federman, N., Anderson, P., Macy, M. E., Davis, L. E., Riedel, R. F., … Meyers, P. (2020). 1620O Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma. In Annals of Oncology (Vol. 31, pp. S972–S972). Elsevier BV. https://doi.org/10.1016/j.annonc.2020.08.1846

Ludwig, J. A., N. Federman, P. Anderson, M. E. Macy, L. E. Davis, R. F. Riedel, J. A. Muscal, et al. “1620O Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma.” In Annals of Oncology, 31:S972–S972. Elsevier BV, 2020. https://doi.org/10.1016/j.annonc.2020.08.1846.

Ludwig JA, Federman N, Anderson P, Macy ME, Davis LE, Riedel RF, et al. 1620O Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma. In: Annals of Oncology. Elsevier BV; 2020. p. S972–S972.

Ludwig, J. A., et al. “1620O Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma.” Annals of Oncology, vol. 31, Elsevier BV, 2020, pp. S972–S972. Crossref, doi:10.1016/j.annonc.2020.08.1846.

Ludwig JA, Federman N, Anderson P, Macy ME, Davis LE, Riedel RF, Muscal JA, Daw NC, Ratan R, Toretsky J, Ianopulos X, Hsu FJ, Breitmeyer JB, Meyers P. 1620O Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma. Annals of Oncology. Elsevier BV; 2020. p. S972–S972.